Clinical Trials

789 enrolled 32 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT05834413 2026-05-13

Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

367 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06195189 2026-05-08

WU-KONG36

Phase 1/2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07573696 2026-05-07

Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06800339 2026-05-06

NEORADJUVANT

Phase 1 Recruiting

18 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07567326 2026-05-05

Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC

78 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05633602 2026-04-17

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

838 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07288034 2026-04-15

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

535 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07526961 2026-04-14

Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

Completed

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03939481 2026-04-13

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

Active not recruiting

1,336 enrolled

GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms

NCT07507188 2026-04-02

INSTAR

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07354061 2026-04-01

TD-ENSEMBLE

Phase 1/2 Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06538038 2026-03-27

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Recruiting

538 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07477808 2026-03-23

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

116 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07472478 2026-03-16

GIVEN

32 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

596 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT05378334 2026-03-10

Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

82 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

126 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07452003 2026-03-05

An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07408635 2026-02-13

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

43 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04297605 2026-02-09

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Phase 1 Recruiting

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05488626 2026-02-05

ARTIA-Lung

Phase NA Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04151940 2026-01-14

PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07330596 2026-01-09

QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC

96 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06899126 2026-01-08

DESTINY-Lung06

Phase 3 Recruiting

686 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07293247 2025-12-22

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

164 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06102057 2025-12-17

PACCELIO

110 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07274384 2025-12-10

HYPERBOLIC

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07271602 2025-12-09

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

104 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05440916 2025-12-02

PRIMM

Phase 2 Completed

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07256002 2025-12-01

Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy

Active not recruiting

10,000 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06652048 2025-11-21

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06228326 2025-10-24

KYANITE-1

Phase 1/2 Recruiting

250 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07215962 2025-10-14

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Active not recruiting

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05775796 2025-10-01

Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)

Phase 2 Completed

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07190027 2025-09-24

Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial

246 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06784791 2025-08-29

NEOpredict-EGF

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07139041 2025-08-24

Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

69 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07135882 2025-08-22

PRIME-Lung

420 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04581824 2025-08-08

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

243 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT06896422 2025-08-07

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

Phase 1 Recruiting

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05691829 2025-07-29

IRRADIATE-Lung

Phase 2 Terminated

19 enrolled 11 charts

Phase NA Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07076836 2025-07-22

Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

82 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Carcinoma, Non-Small-Cell Lung

NCT06829641 2025-06-27

Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC

Not yet recruiting

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07035860 2025-06-25

Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer

Not yet recruiting

34 enrolled